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Abstract
Background—Adenomatous polyps are the most common precursor to colorectal cancer (CRC), 
the second leading cause of cancer death in the United States. We sought to learn more about early 
events of carcinogenesis by investigating shifts in the gut microbiota of patients with adenomas.
Methods—We analyzed 16S rRNA gene sequences from the fecal microbiota of patients with 
adenomas (n=233) and without (n=547).
Results—Multiple taxa were significantly more abundant in patients with adenomas, including 
Bilophila, Desulfovibrio, pro-inflammatory bacteria in the genus Mogibacterium, and multiple 
Bacteroidetes species. Patients without adenomas had greater abundances of Veillonella, 
Firmicutes (Order Clostridia), and Actinobacteria (family Bifidobacteriales). Our findings were 
consistent with previously reported shifts in the gut microbiota of CRC patients. Importantly, the 
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altered adenoma profile is predicted to increase primary and secondary bile acid production, as 
well as starch, sucrose, lipid, and phenylpropanoid metabolism.
Conclusions—These data hint that increased sugar, protein, and lipid metabolism along with 
increased bile acid production could promote a colonic environment that supports the growth of 
bile-tolerant microbes such as Bilophilia and Desulfovibrio. In turn, these microbes may produce 
genotoxic or inflammatory metabolites such as H2S and secondary bile acids, which could play a 
role in catalyzing adenoma development and eventually CRC.
Impact—This study suggests a plausible biological mechanism to explain the links between shifts 
in the microbiota and CRC. This represents a first step toward resolving the complex interactions 
that shape the adenoma-carcinoma sequence of CRC and may facilitate personalized therapeutics 
focused on the microbiota.
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1. Introduction
Adenomatous polyps, or adenomas, have long been recognized as a critical precursor to 
colorectal cancer (CRC) (1, 2), the second leading cause of cancer deaths in the United 
States (3). Although screening (4–6) and lifestyle (7–10) play important roles in CRC 
prevention, identifying a causal mechanism of mutagenesis is essential to understand the 
adenoma-carcinoma sequence and to develop new and personalized prevention strategies. 
The gut microbiota has recently been implicated in adenoma and CRC pathogenesis (11, 12) 
and offers a promising avenue for personalized prevention (13). Importantly, many of the 
risk factors for CRC—including diet (high red meat / high fat / low fiber) (8, 14), obesity 
(15), physical activity (10), smoking (7), and alcohol use (9)—also have significant effects 
on the gut microbial community (16). Because the gut microbiota alters the metabolic 
environment of the host, it may directly or indirectly influence mutagenesis rates (11, 17), 
and thus carcinogenesis.
Previous studies on the microbiome of individuals with adenomas have identified many 
microbes associated with these particular polyps (Table 1). However, most of these studies 
lack functional analyses necessary to suggest a mechanistic link between microbiota, 
adenoma development, and carcinogenesis. Microbial functionality, which can be predicted 
based on microbial genomes, provides greater insight into the microbial ecology of the colon 
by not only indicating what taxa are differentially abundant, but also the putative function of 
these taxa (18). Without functional analyses, it is difficult to elucidate the role of microbes in 
the adenoma-carcinoma sequence because microbial taxa associated with adenomas and 
CRC vary widely by study (11, 12). Additionally, many subject cohorts are relatively 
underpowered, ranging in size from 6 to 67 individuals with adenomas (see Table 1), making 
it even more difficult to identify subtle microbial or functional changes that may be 
underlying adenoma/CRC pathogenesis. Moreover, meta-analysis on these data is 
particularly challenging due to multiple biases attributed to extraction methods (19), PCR 
regions (20), and collection protocols (21). As such, a well-powered study with a uniform 
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collection/extraction protocols and functional analyses is needed to more definitively probe 
the link between the microbial community and adenoma development.
In this study, we compared the fecal microbiota of patients with (n=233) and without 
adenomas (n=547). Our aim was twofold: to determine whether gut microbial communities 
can be used to predict the presence of adenomas and to elucidate the microbial ecology 
underlying the adenoma-carcinoma sequence. Here we report significant shifts in the gut 
microbiota composition of patients with adenomas and use these changes and their predicted 
functional consequences to propose a model linking diet, gut microbes, and the development 
of adenomas, the precursors to CRC.
2. Materials and Methods
2.1 Subject enrollment
Fecal samples (n=780) were selected from a freezer archive of stools collected without 
preservative buffer. All stool samples came from patients presenting for standard screening 
colonoscopy between 2001–2005 at multiple medical centers, including the Mayo Clinic, 
Rochester, MN; Kaiser Permanente in Sacramento and Oakland, CA; Oregon Health & 
Science University, Portland, OR; University of Colorado Health Sciences Center, Denver, 
CO; Roswell Park Cancer Institute, Buffalo, NY; Indiana University Medical Center, 
Indianapolis, IN; and other North Central Cancer Treatment Group institutions (22). All 
patients were 50–80 years old and were voluntarily enrolled prior to presenting for 
colonoscopy (Fig. 1). Exclusion criteria for the original study comprised premenopausal 
women, hematochezia or melena within the month prior to enrollment, prior colorectal 
resection, coagulopathy or anticoagulant use, chemotherapy within 3 months of enrollment, 
contraindications to colonoscopy, inability to desist from therapeutic doses of nonsteroidal 
anti-inflammatory drugs (NSAIDS), aerodigestive cancer within 5 years of enrollment, a 
fecal occult blood test within the year prior to enrollment, and colorectal evaluation (e.g., 
sigmoidoscopy or colonoscopy) within 10 years of enrollment. Patients at high risk for CRC
—including patients with familial adenomatous polyposis, cancer syndromes, inflammatory 
bowel disease, prior CRC or adenomas, or ≥2 first-degree relatives with CRC—were also 
excluded.
Standard diagnostic colonoscopies were performed on all patients and included intravenous 
sedation (unless otherwise requested); inspection of the colonic mucosal surfaces up to the 
point of the cecum; and lesion assessment, including recording the location, size, number, 
and architecture all polypoid lesions. All polyps/lesions removed from the colon were 
submitted for histological classification and reviewed by the same pathologist. Fecal 
samples from patients in which at least one adenoma > 1 cm was identified were included in 
the “adenoma” group. Fecal samples from patients with no polyps were included in the 
“non-adenoma” group. Fecal samples from patients who were diagnosed with CRC were 
excluded from analysis.
Approval for this study was granted by the Mayo Clinic’s Institutional Review Board. Fecal 
samples were collected under protocol #15-004021, from patients who had previously 
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enrolled under protocol #532-00, undergone standard screening colonoscopies, and given 
consent for the use of their samples in future research studies.
2.2 Sample collection and processing
Fecal samples were self-collected by patients after enrollment and up to 3 months prior to 
bowel preparation and colonoscopy. Samples were collected in a bucket container mounted 
to a toilet seat. Promptly after defecation, whole stools were express shipped on ice in 
insulated containers to a central lab where they were immediately archived at −80°C until 
further processing. Samples received >48 hours after defecation were disqualified. In 
preparation for DNA extraction, a 4-mm biopsy punch (Miltex, York, PA, USA) was used to 
collect a core sample from the still-frozen feces. The frozen fecal core was immediately 
transferred into Chemagic lysis buffer (PerkinElmer, Baesweiler, Germany). DNA extraction 
was performed on a Chemagic MSM I (PerkinElmer), using the Chemagic DNA blood 
special kit (PerkinElmer). DNA quantification and amplification was performed as 
previously described (23). The 16S rRNA sequencing library was constructed at the 
University of Minnesota Genomics Center, and sequencing was performed at the Mayo 
Clinic Medical Genomics Facility, on a MiSeq using a MiSeq Reagent Kit v3 (2 × 300, 600 
cycles, Illumina Inc., San Diego, CA, USA).
2.3 Sequence processing
After sequencing, adapter-primer sequences were removed from reads as previously 
described (23). Sequences were then processed via the IM-TORNADO bioinformatics 
pipeline, using a 97% identity threshold to assign operational taxonomic units (OTUs) (24). 
Paired R1 and R2 reads were analyzed. In total, 17,579,026 reads passed quality control. 
Singleton OTUs as well as samples with less than 2,000 reads were removed. Sequencing 
data are available at SRA Study accession SRP070783.
2.4 Statistical analyses
2.4.1 α-diversity and β-diversity—To compare the microbial communities of the 
adenoma and non-adenoma groups, we summarized microbiota data using both α-diversity 
and β-diversity measures. Two α-diversity metrics were used, the observed OTU number 
and the Shannon index. The observed OTU number reflects species richness, whereas the 
Shannon index places more weight on species evenness. β-diversity, by contrast, indicates 
the shared diversity between bacterial populations in terms of ecological distance; different 
distance metrics provide distinctive views of community structure. Two β-diversity 
measures, unweighted and weighted UniFrac distances, were calculated using the OTU table 
and a phylogenetic tree (with the “GUniFrac” function in the R package GUniFrac) (16). 
The unweighted UniFrac reflects differences in community membership (i.e., the presence 
or absence of an OTU), whereas the weighted UniFrac mainly captures differences in 
abundance. Rarefaction was performed on the OTU table before calculating the distances.
To assess the association between adenoma status and α-diversity, we fitted a linear 
regression model to the α-diversity metrics after rarefaction, adjusting for technical 
covariates such as sequencing batch. A Wald test was used to determine significance. To 
assess the association between adenoma status and β-diversity measures, we used the 
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recently proposed MiRKAT, which is a kernel-based association test based on ecological 
distance matrices (25). We also used MiRKAT to assess the relationship between polyp 
characteristics (size, number, location, architecture, histology) and β-diversity measures. In 
individuals with multiple polyps, a single polyp location was chosen at random, and the 
most severe architecture and histology per patient were selected for analysis. MiRKAT 
produces analytic p-values for individual distance metrics, as well as a permutation-based 
omnibus p-value that combines multiple distance metrics, for a more robust and powerful 
assessment of significance. For the omnibus test, significance was assessed using 1,000 
permutations, and the covariate - sequencing batch - was adjusted if necessary. Ordination 
plots were generated using principal coordinate analysis as implemented in R (“cmdscale” 
function in the R ‘vegan’ package).
2.4.2 Differential abundance analysis—We conducted differential abundance analysis 
at the phylum, class, order, family, and genus levels, and we filtered out taxa with prevalence 
less than 10%. We normalized the count data into relative abundances (proportions) by 
dividing by the total read count; taxa with a maximum proportion less than 0.2% were 
excluded from testing to reduce the number of the tests. To identify differentially abundant 
taxa while accommodating covariates (e.g., sequencing batch) and the non-normality of the 
count data, we used a permutation test in which a regular linear model was fitted, with taxa 
proportion data as the outcome variable. To reduce the effects of outliers, taxa proportion 
data was square-root transformed. Statistical significance was assessed using 1,000 
permutations with the F-stat as the test statistic. False discovery rate (FDR) control (B-H 
procedure, ‘p.adjust’ in standard R packages) was used to correct for multiple testing, and 
FDR-adjusted p-values or q-values less than 0.2 were considered significant. This q-value 
cutoff was chosen to avoid missing important taxa with small effect sizes and is a 
significance threshold frequently utilized in human microbiome studies (26, 27). To quantify 
the effect size of the differential taxa, we used the fold change of the mean relative 
abundance between the normal and adenoma groups.
2.4.3. Predictive modeling based on random forests—The machine learning 
algorithm random forests (RF) was used to predict adenoma status based on the microbiota 
profile (genus-level proportion data) using default parameters of the R implementation of the 
algorithm (28). The RF algorithm, due to its non-parametric assumptions, can detect both 
linear and nonlinear effects and potential taxon-taxon interactions, thereby identifying the 
taxa that best discriminate between groups. Boruta variable selection was applied to select 
the most discriminatory taxa based on importance values produced by RF (29). The Boruta 
method spikes abundance data with “shadow” taxa, which are shuffled versions of real taxa. 
This enables us to assess whether the importance of a given taxon is significant, that is, 
whether the importance is discernible from the effects that arise from random fluctuations 
(shadow taxa). We then assessed the ability of the Boruta-selected taxa to predict adenoma 
status using the receiver operating characteristic (ROC) curve, which was estimated using 
the 0.632+ bootstrap method to more accurately assess error rates (30).
2.4.4. Functional data analysis—PICRUSt was used to infer the abundance of 
functional categories (KEGG metabolic pathways and COG functional groups) based on the 
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16S rRNA data, and differential abundance analysis was performed using the same 
permutation test that was used for the taxon analysis (18). No prevalence-based filtering was 
applied before differential abundance testing, since most of the functional categories are 
shared across subjects. All statistical analyses were performed in R 3.0.2 (R Development 
Core Team, Vienna, Austria).
3. Results
Cases (“adenoma” group) comprised 233 patients with at least one large adenoma (≥ 1 cm); 
controls included 547 patients with no polyps on colonoscopy (“non-adenoma” group). The 
groups did not differ with regard to the potential confounders of age, sex, race, history of 
smoking, history of cancer, or diagnosis of CRC or polyps in first-degree relatives (Table 2).
The overall composition of the groups’ gut microbial communities appeared similar at the 
levels of phylum, family, and genus (Supplementary Fig. S1A). The groups did not differ 
significantly in terms of microbial species richness (P=0.21) or diversity (Shannon Index; 
P=0.23) (Supplementary Fig. S1B and S1C). Neither did they cluster in PCoA plots using 
unweighted or weighted UniFrac distance metrics (Supplementary Fig. S1D and S1E). 
However, our large sample size allowed us to detect small yet statistically significant 
differences in microbial composition between the adenoma and non-adenoma groups 
(MiRKAT omnibus P=0.032). No differences in microbial composition were detected based 
on polyp size, architecture, or location, but polyp number was significant (MiRKAT 
omnibus P=0.035) and histology (hyperplastic, low grade dysplasia, or high grade dysplasia) 
was marginally significant (MiRKAT omnibus P=0.091; Supplementary Table S1).
Next, we identified 31 specific taxa that differed in abundance between patients with and 
without adenomas (Fig. 2 q <0.2) Taxa that were more abundant in the adenoma group 
included multiple OTUs in the Bacteroidetes phyla and Deltaproteobacteria class—including 
OTUs in the Bilophila, Desulfovibrio, Sutterella, and Mogibacterium genera. Taxa more 
common in the non-adenoma group included Firmicutes, such as OTUs in the Clostridia 
class and Veillonella genus, as well as OTUs in the Bifidobacteriales order and Haemophilus 
genus. Despite moderate effect sizes (fold change range: 1.06–2.77), these significant results 
indicate that the microbiota in the adenoma group systematically differs from the non-
adenoma group.
We next assessed the utility of the gut microbiota as a clinical biomarker for adenomas using 
random forests-based prediction. Boruta feature selection was used to select the most 
predictive taxa to improve prediction. Of the 31 taxa identified by differential abundance 
testing, the Boruta algorithm identified four genera that significantly predicted adenoma 
status: Streptococcus and Veillonella, which were enriched in the non-adenoma group, and 
Mogibacterium and Sutterella, which were enriched in the adenoma group (Fig. 3; for heat 
map see Supplementary Fig. S2). The Bilophila genus was also more predictive than most 
other genera included in this analysis; however, this genera did not exceed the threshold for 
significance. An ROC curve generated with the four significantly predictive taxa resulted in 
an area under the curve (AUC) of 0.6599 (Fig. S3; DeLong test, p = 0.001). Although 
significant, this level of sensitivity/specificity is too low for consideration as a clinical 
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biomarker for adenomas. Thus, this analysis indicates that although the abundance of 
Streptococcus, Veillonella, Mogibacterium, and Sutterella is not sufficient to reliably 
identify samples from patients with adenomas, the levels of these genera are consistently 
altered in their respective groups.
To determine whether the taxonomic differences between the groups’ microbiota 
corresponded to functional changes, we performed a predictive functional analysis of the 
16S rRNA sequences present (Fig. 4, q<0.2). PICRUSt analyses predicted that the adenoma 
group’s microbiota exhibits increased primary and secondary bile acid synthesis; increased 
galactose, starch and sucrose, and sphingolipid metabolism; and increased phenylpropanoid 
biosynthesis. By contrast, the non-adenoma group’s microbiota is predicted to exhibit 
increased biosynthesis of unsaturated fatty acids and increased purine, pyrimidine, D-
Alanine, nicotinate, and nicotinamide metabolism.
4. Discussion
In this study, we report significant differences in the microbial composition of individuals 
with adenomas. We also observe differences based on polyp number and histology but not 
size, architecture, or polyp location, suggesting that microbial communities associated with 
polyps change (or are detectable) with some but not all aspects of polyp severity. We 
identified 31 taxa that were differentially abundant among patients with and without 
adenomas, and four of these taxa were significantly predictive of adenoma status, although 
they could not be used to reliably classify samples. Based on the 16S sequences present in 
each group, we also identified putative metabolic shifts between the microbiota of the 
adenoma and non-adenoma groups.
Links with CRC have already been reported in many of the taxa we identified as 
differentially abundant in individuals with adenomas. This suggests that changes in the 
microbial community associated with adenomas may represent early events in the pathway 
leading to CRC. For example, we identified increased levels of Bilophila, Desulfovibrio, 
Bacteroidetes, and Mogibacterium in individuals with adenomas. Both Bilophila and 
Desulfovibrio produce genotoxic hydrogen sulfide (H2S) as an end product of anaerobic 
respiration (31–33) and have been associated with CRC in other studies (34, 35). In addition, 
multiple studies have reported elevated proportions of Bacteroidetes in patients with 
adenomas (36, 37) or CRC (38, 39) (but not all; see (40)). Bacteroides fragilis, in particular, 
causes colitis-associated carcinogenesis (41). Finally, Mogibacterium is an oral bacterium 
associated with periodontal disease and root canal infections, and it, too, has been linked to 
CRC (42–44).
Other taxa differentially abundant in individuals with adenomas are also plausible 
contributors to carcinogenesis. For example, Sutterella, a genus highly predictive of 
adenoma status (Fig. 3), may play a role in inflammation, as it has been linked to active 
colitis in a mouse model of inflammatory bowel disease (45). Gastrointestinal inflammation 
has been strongly linked to CRC pathogenesis (11). By contrast, Veillonella, also highly 
predictive of adenoma status but enriched in patients without adenomas, may exert a 
protective role in the colon (46) along with other taxa enriched in this group, including 
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Firmicutes and Actinobacteria (family Bifidobacteriales) (47). Notably, we did not identify 
an enrichment of Fusobacterium or Porphyromonadaceae in individuals with adenomas, as 
reported in other studies (39, 48, 49). This may have been due to differences in study 
populations, fecal collection and preservation techniques (21, 50), library preparation (51), 
or primers and sequencing platforms (52, 53).
We evaluated microbial alterations in tandem with predictive functional differences 
identified by PICRUST. In an analysis of Human Microbiome Project data, PICRUST 
produced an average correlation of 0.8 between predicted functions and actual functions 
identified through deep metagenomic sequencing (18). Additionally, PICRUST produced 
more accurate and reliable functional predictions than shallow metagenomic sequencing 
(18). Despite these strengths of PICRUST, predictive functions should be examined with 
care, as genomes and functions of the microbes present in a given sample may differ from 
the genomes and functions upon which PICRUST builds its predictions. The results from 
our predictive functional analysis suggest a link the between microbial shifts observed in 
individuals with adenomas to metabolic pathways that have previously been associated with 
dietary risk factors common in a Western diet. The adenoma microbiota was characterized 
by putative functional groups associated with galactose, sphingolipid, and starch/sucrose 
metabolism, as well as phenylpropanoid biosynthesis. Importantly, diets high in dairy result 
in increased galactose metabolism; diets high in fat result in increased lipid/sphingolipid 
metabolism (54); diets high in refined starches and sugars lead to increased starch/sucrose 
metabolism (55); and diets high in protein result in increased phenylpropanoid biosynthesis 
(56). Diets high in animal fat and protein also lead to increased BA production (57). 
Interestingly, the adenoma microbiota is predicted to display increased levels of primary and 
secondary bile acid (BA) synthesis. These functional predictions suggest that individuals 
with adenomas are consuming diets higher in fat, sugar, starch, protein, and dairy than non-
adenoma individuals. These findings are consistent with multiple epidemiological studies, 
which have drawn links between a Western diet (high in fat, dairy, meat, and sugars) and the 
incidence of adenomas (58–60). This suggests a potential link between diet and the 
molecular mechanisms involved in adenoma pathogenesis.
We propose the following mechanism linking diet, the microbiota, and the adenoma-
carcinoma sequence: Diets high in fat and protein increase production of primary BAs, 
which help digest and absorb lipids in the small intestine (61, 62). This promotes the growth 
of bile-tolerant bacteria such as Bilophila and some species of Desulfovibrio. Blooms of 
these species may increase the production of genotoxic metabolites such as H2S (61, 62). In 
addition, the colon microbiota can deconjugate primary bile acids to form secondary BAs 
(62, 63), and some of these secondary BAs, such as lithocholic and deoxycholic acid, have 
cytotoxic and genotoxic effects (62–66). Elevated levels of secondary BAs and pro-
inflammatory bacteria such as Mogibacterium and Sutterella may result in the perfect storm 
of DNA damage and inflammation, leading to adenoma development and eventually 
malignant transformation.
Several limitations of our study warrant mention. Three include a lack of information on 
participants’ diet, body mass index (BMI), and recent antibiotic use. Without dietary 
information, we cannot confirm that the adenoma group consumed a diet higher in sugar, 
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animal fat, and protein; although, previous studies have indicated a link between Western 
diet and adenomas (58, 59). Additionally, we are also unable to determine whether BMI acts 
as a confounder; it is certainly possible, as the gut microbiome of obese individuals differs 
significantly from the microbiome of lean individuals (67), and higher BMI has been 
associated with adenoma development (68). However, obese / high BMI phenotypes are 
commonly associated with increased relative abundances of microbes in the phylum 
Firmicutes while lean phenotypes are associated with increased abundances of Bacteroidetes 
phylum microbes (67, 69). In our study, individuals with adenomas had increased 
abundances of Bacteroidetes microbes while individuals without adenomas had increased 
abundances of Firmicutes phylum microbes. This is opposite to what we would have 
expected if BMI was the main driver of adenoma development; thus, we suggest BMI was 
not a strong confounder in our data set. Lack of antibiotic data prevents us from excluding or 
analyzing data based on antibiotic use, which can dramatically alter the gut microbiota (70); 
although, we have no a priori reason to believe that either group would exhibit increased 
antibiotic use in relation to the other. Finally, the cross-sectional nature of our data does not 
allow us to parse correlation versus causation between microbial alterations and adenoma 
status. While our results show that observed microbial changes lack the specificity and 
sensitivity to serve as a clinical biomarker for adenomas, these findings provide important 
insights into mechanisms that may be driving adenoma development.
This study represents the largest study on microbial communities associated with adenomas 
to date. This robust data set allowed us to detect subtle microbial changes that may be key to 
understanding how a healthy colon develops adenomas, which can then transform into 
carcinomas. We also adjusted our analyses for multiple comparisons, which not all studies 
on adenoma microbiota opt to do (37, 71, 72). Sample collection is another strength of this 
study. All fecal samples from individuals in the adenoma and non-adenoma groups were 
shipped on ice and received and frozen at -80°C within 48 hours of defecation. Previous 
studies have demonstrated that fecal microbial communities stored at ambient temperatures 
for up to 24 hours, are relatively unaffected (21), and no significant changes in microbial 
diversity or composition are detected in fecal samples stored at 4°C for up to 72 hours (73). 
Additionally, long term storage of fecal samples at -80°C seems to have little effect on 
overall microbial composition (50, 74); although, no study, to our knowledge, has examined 
fecal preservation in samples over 10 years old, as is the case with samples in this study. 
Notably, we only examined fecal microbiota and not the mucosal-associated microbiota, 
which has been reported to differ in composition and diversity (75). Every individual 
sampled in this study underwent a complete colonoscopy with full visualization of the colon 
from rectum to cecum, and colonoscopy is regarded as the most robust reference standard 
for presence or absence of polyps. Polyps removed during colonoscopies were all reviewed 
and classified by the same pathologist. Finally, our study included predictive functional 
analyses based on the microbial communities of the adenoma and non-adenoma groups. 
Functional analyses have not been performed on previous adenoma datasets, and this effort 
suggested key insights as to how the host and microbial community may be interacting 
within the context of adenoma development.
In conclusion, we have shown that the composition of the gut microbiota in individuals with 
adenomas differs significantly from that of healthy individuals and resembles the microbiota 
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of individuals with CRC. Moreover, we suggest that these shifts may be consistent with the 
effects of the Western diet and are predicted to result in metabolic changes that could 
increase rates of cellular damage and mutagenesis in the gut. Collectively, our findings 
support a proposed model in which diet alters the microbial composition of our 
gastrointestinal tract, leading to an environment conducive to the development of adenomas, 
and potentially CRC. Future studies are needed to assess the effects of diet on the metabolic 
environment of the gut and the microbial community. Genotoxic metabolites such as H2S 
and secondary bile acids should also be examined in relation to adenoma and carcinoma 
development. Identifying key interactions between diet, microbial community, and 
metabolites that catalyze the adenoma-carcinoma sequence will give us a basis for 
personalized therapeutics aimed at preventing CRC.
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Figure 1. 
Subject enrollment flowchart.
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Figure 2. 
Thirty-one taxa differ in abundance between patients with and without adenomas. A) 
Relative abundance of OTUs in each group, across taxonomic levels. B) −log(P value) of 
these taxa’s differential abundance. C) Cladogram of the taxa that differed between groups.
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Figure 3. 
Based on the results of a random forests (RF) algorithm, four taxa significantly predict 
adenomatous polyp status: Streptococcus, Veillonella, Mogibacterium, and Sutterella. The 
four taxa that are significant predictors are shown in green. Blue boxplots correspond to 
minimal, average and maximum Z score of a shadow taxa. Red, yellow and green boxplots 
represent Z scores of rejected, tentative and confirmed taxa respectively.
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Figure 4. 
Functional differences, predicted using 16S sequencing data, between the gut microbial 
communities of patients with and without adenomas, A) Pink bars represent the −log(P 
value) of KEGG metabolic pathways predicted to be more common among the microbiota of 
individuals with adenomatous polyps. Turquoise bars represent the effect sizes of functions 
predicted to be more common among the microbiota of individuals without polyps. B) 
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Summary of the log(P value) of COG groups predicted to differ between the groups; colors 
as in (A).
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Table 2
Demographics of the adenoma and non-adenoma groups.
Adenoma
(n=233)
Non-adenoma
(n=547)
p-value
Age (mean, SD) 66.5, 6.9 66.5, 6.9 0.60
Sex (n, %)
0.98  Female 100 (42.9) 237 (43.3)
  Male 133 (57.1) 310 (56.7)
Race (n, %)
0.30
  White 223 (95.7) 503 (92)
  Black 3 (1.3) 14 (2.6)
  Hispanic 4 (1.7) 14 (2.6)
  Asian 0 (0) 8 (1.5)
  Native American 0 (0) 2 (0.5)
  Other / Unknown 3 (1.3) 5 (0.9)
Ever smoker (n, %) 138 (59.2) 310 (56.7) 0.56
History of cancer,
any type (n, %) 44 (18.9) 116 (21.2) 0.52
First degree relative with
colorectal cancer (n, %) 35 (15) 89 (16.3) 0.74
First degree relative
with polyps (n, %) 25 (10.7) 47 (8.6) 0.82
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